Warning! GuruFocus detected
2 Severe warning signs
with DVA.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description

DaVita Inc
NAICS : 621492
SIC : 8092
ISIN : US23918K1088
Compare
Compare
Traded in other countries / regions
DVA.USA0I7E.UKTRL.GermanyDVAI34.BrazilDVA.Mexico Index Membership
S&P 500Russell 1000Russell 3000 IPO Date
1995-10-31Description
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.07 | |||||
Equity-to-Asset | 0.01 | |||||
Debt-to-Equity | 99.63 | |||||
Debt-to-EBITDA | 4.43 | |||||
Interest Coverage | 4.16 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 1.74 | |||||
Beneish M-Score | -2.78 | |||||
WACC vs ROIC |
Growth Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 11.6 | |||||
3-Year EBITDA Growth Rate | 11.4 | |||||
3-Year EPS without NRI Growth Rate | 2 | |||||
3-Year FCF Growth Rate | 12.7 | |||||
3-Year Book Growth Rate | -42.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 14.36 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 4.1 |
Momentum Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 42.83 | |||||
9-Day RSI | 40.52 | |||||
14-Day RSI | 41.33 | |||||
3-1 Month Momentum % | -11.45 | |||||
6-1 Month Momentum % | -3.96 | |||||
12-1 Month Momentum % | 13.56 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.26 | |||||
Quick Ratio | 1.21 | |||||
Cash Ratio | 0.28 | |||||
Days Inventory | 5.77 | |||||
Days Sales Outstanding | 64.36 | |||||
Days Payable | 21.51 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 6.1 | |||||
Shareholder Yield % | 6.52 |
Profitability Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 32.91 | |||||
Operating Margin % | 15.25 | |||||
Net Margin % | 7.31 | |||||
FCF Margin % | 11.44 | |||||
ROE % | 149.92 | |||||
ROA % | 5.44 | |||||
ROIC % | 9.98 | |||||
3-Year ROIIC % | -61.9 | |||||
ROC (Joel Greenblatt) % | 34.06 | |||||
ROCE % | 13.89 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 12.99 | |||||
Forward PE Ratio | 12.81 | |||||
PE Ratio without NRI | 14.32 | |||||
Shiller PE Ratio | 22.55 | |||||
Price-to-Owner-Earnings | 11.16 | |||||
PEG Ratio | 1.01 | |||||
PS Ratio | 0.94 | |||||
PB Ratio | 93.04 | |||||
Price-to-Free-Cash-Flow | 8.14 | |||||
Price-to-Operating-Cash-Flow | 6.01 | |||||
EV-to-EBIT | 12.17 | |||||
EV-to-Forward-EBIT | 11.27 | |||||
EV-to-EBITDA | 8.94 | |||||
EV-to-Forward-EBITDA | 8.28 | |||||
EV-to-Revenue | 1.9 | |||||
EV-to-Forward-Revenue | 1.69 | |||||
EV-to-FCF | 16.61 | |||||
Price-to-GF-Value | 1.1 | |||||
Price-to-Projected-FCF | 0.62 | |||||
Price-to-DCF (Earnings Based) | 0.86 | |||||
Price-to-DCF (FCF Based) | 0.32 | |||||
Price-to-Median-PS-Value | 0.89 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.21 | |||||
Earnings Yield (Greenblatt) % | 8.22 | |||||
FCF Yield % | 13.14 | |||||
Forward Rate of Return (Yacktman) % | 21.29 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:DVA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
DaVita Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 12,815.55 | ||
EPS (TTM) ($) | 10.74 | ||
Beta | 1.13 | ||
3-Year Sharpe Ratio | 0.34 | ||
3-Year Sortino Ratio | 0.55 | ||
Volatility % | 40.29 | ||
14-Day RSI | 41.33 | ||
14-Day ATR ($) | 5.389513 | ||
20-Day SMA ($) | 147.151 | ||
12-1 Month Momentum % | 13.56 | ||
52-Week Range ($) | 130.96 - 179.6 | ||
Shares Outstanding (Mil) | 80 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 8 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
DaVita Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
DaVita Inc Stock Events
Event | Date | Price ($) | ||
---|---|---|---|---|
No Event Data |
DaVita Inc Frequently Asked Questions
What is DaVita Inc(DVA)'s stock price today?
The current price of DVA is $139.56. The 52 week high of DVA is $179.60 and 52 week low is $130.96.
When is next earnings date of DaVita Inc(DVA)?
The next earnings date of DaVita Inc(DVA) is 2025-05-02 Est..
Does DaVita Inc(DVA) pay dividends? If so, how much?
DaVita Inc(DVA) does not pay dividend.
Guru Commentaries on NYSE:DVA
No articles.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |